source
- Biotech investors gamble on M&A. Some drugmakers are betting on themselves instead.Young biotechs usually get acquired instead of profitably selling their own medicines. A growing number are proving they can, which could make the sector more broadly appealing to investors, some say.BioPharma Dive · 3mo ago↗ source
- STAT+: Eli Lilly enlists AI startup for next-generation gene editorsEli Lilly's deal with Profluent aims to go beyond CRISPR by using AI-designed enzymes to insert entire genes. It could reshape genetic medicine.STAT · 3mo ago↗ source
- Opinion: It’s time to seize the rare bipartisan opening to address microplastics“This could be the start of serious action on microplastics. Or it could end up as a headline with little behind it,” write Tim Ryan and Justin Zorn.